Zelira Therapeutics positions for future growth with transition to US-based leadership team led by Dr Oludare Odumosu

Zelira Therapeutics Ltd’s (ASX:ZLD) (OTCQB:ZLDAF) (FRA:G1G) strategic consolidation of its operations will see leadership of the company transfer to the US-based team, with Dr Oludare Odumosu assuming the role of global managing director. 

Dr Richard Hopkins has decided to step down as chief executive officer and managing director ex-USA effective May 15, 2021. 

He will however continue in his role while assisting and supporting the company through the transition period. 

Strong achievements over past 12 months

Dr Hopkins said: “I have enjoyed establishing and leading the Australian-based Zelira team, whose achievements over the past 12 months, in particular, have been strong.

“These include helping facilitate the merger, delivering successful outcomes to two world-class clinical trials and launching three products into the Australian market.

“I’m looking forward to continuing to work with Dr Odumosu during the transition period.”

Position for future growth

Zelira chairman Osagie Imasogie said: “Richard has been instrumental in helping facilitate Zelira’s merger and transition to a global revenue-generating company.

“He has overseen the development of a pipeline of clinically validated products that recently launched on the Australian market and are now poised to enter global markets.

“With these outcomes successfully delivered, the time is right to position the company for future growth by transitioning to a US-based leadership team.

“This will allow Zelira to optimise its exposure to the rapidly expanding US cannabis sector while also continuing to grow its revenues in ex-USA markets.

“We thank Richard for all his efforts in taking Zelira’s ex-US operations forward during his tenure and wish him well in his future career.”

Story by ProactiveInvestors